Wexford Capital LP Abb Vie Inc. Transaction History

Wexford Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $958,920 - $1.09 Million	6,000 New	6,000 $1.09 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $479,553 - $596,773	3,619 New	3,619 $487,000
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $3.01 Million - $3.31 Million	-29,424 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $6.3 Million - $8.51 Million	-78,265 Reduced 72.68%	29,424 $3.15 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $1.6 Million - $1.88 Million	18,660 Added 20.96%	107,689 $9.43 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $6.53 Million - $8.74 Million	89,029 New	89,029 $8.74 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.